FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-09-11T02:35:06.574Z. Latest historical point 2026-09-10. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-09-11T02:35:06.574Z. Latest historical point 2026-09-10. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-09-11T02:35:06.574Z. Latest historical point 2026-09-10. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-09-11T02:35:06.574Z. Latest historical point 2026-09-10. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-09-11T02:35:06.574Z. Latest historical point 2026-09-10. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-09-11T02:35:06.574Z. Latest historical point 2026-09-10. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-09-11T02:35:06.574Z. Latest historical point 2026-09-10. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
Product / business disclosures (FY 2025)
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Products, Other HIV$20.75B
Cell Therapy Products, Total Cell Therapy Product Sales$2.18B
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Geographic disclosures (FY 2025)
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
UNITED STATES$20.88B
Europe$5.06B
Other International$3.50B
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
$7.80B
vs Estimate
$7.40B
Beat
GILD Analyst Ratings
Consensus Rating
Buy
Based on 27 analysts
Strong Buy
6
Buy
15
Hold
6
Sell
0
Strong Sell
1
Average Price Target
$157.41
+8.7% upside
Low
$123.00
Current
$144.81
High
$180.00
GILD Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
Period
Low
Avg
High
# Analysts
Quarter ending Sep 2026
$1.90
$2.12
$2.27
13
Quarter ending Dec 2026
$1.97
$2.14
$2.27
12
Quarter ending Mar 2027
$2.24
$2.30
$2.39
5
Quarter ending Jun 2027
$2.42
$2.49
$2.58
5
Annual
Period
Low
Avg
High
# Analysts
FY 2026
$-0.62
$-0.46
$-0.32
16
FY 2027
$9.38
$9.89
$11.07
16
Revenue Estimates
Quarterly
Period
Low
Avg
High
# Analysts
Quarter ending Sep 2026
$7.67B
$7.76B
$7.87B
11
Quarter ending Dec 2026
$8.11B
$8.13B
$8.16B
10
Quarter ending Mar 2027
$7.28B
$7.44B
$7.64B
9
Quarter ending Jun 2027
$7.85B
$8.02B
$8.24B
9
Annual
Period
Low
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
